BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zepuping (jaktinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zepuping (jaktinib)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07445893-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Zepuping (jaktinib): Phase na readout est. (NCT07445893)
DESCRIPTION:Zepuping (jaktinib)\, phase na.\nStudy: A Clinical Study of Gec
 acitinib Combined With Pegylated Interferon in Patients With PV\nEstimated
  primary completion: 30 December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/jaktinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07445893
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07157306-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Zepuping (jaktinib): Phase 2 readout est. (NCT07157306)
DESCRIPTION:Zepuping (jaktinib)\, phase 2.\nStudy: Gecacitinib Combined Wit
 h Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresecta
 ble Hepatocellular Carcinoma\nEstimated primary completion: 1 January 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/jaktinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07157306
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07565597-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Zepuping (jaktinib): Phase 1 readout est. (NCT07565597)
DESCRIPTION:Zepuping (jaktinib)\, phase 1.\nStudy: A Pharmacokinetic Study 
 of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.\nEstim
 ated primary completion: February 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/jaktinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07565597
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07197112-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Zepuping (jaktinib): Phase 2 readout est. (NCT07197112)
DESCRIPTION:Zepuping (jaktinib)\, phase 2.\nStudy: Study of Gecacitinib in 
 the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxoliti
 nib-containing Second-line Therapy\nEstimated primary completion: 1 Februa
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/jaktinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0719711
 2
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07012304-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Zepuping (jaktinib): Phase 1/2 readout est. (NCT07012304)
DESCRIPTION:Zepuping (jaktinib)\, phase 1/2.\nStudy: Gecacitinib for cGVHD:
  Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy\nEstima
 ted primary completion: 28 February 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/jaktinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07012304
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06903377-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Zepuping (jaktinib): Phase 1/2 readout est. (NCT06903377)
DESCRIPTION:Zepuping (jaktinib)\, phase 1/2.\nStudy: Study of ZG005 Combine
 d With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer\nE
 stimated primary completion: April 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/jaktinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06903377
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06883526-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Zepuping (jaktinib): Phase 1/2 readout est. (NCT06883526)
DESCRIPTION:Zepuping (jaktinib)\, phase 1/2.\nStudy: Study of ZG005 in Comb
 ination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma\
 nEstimated primary completion: April 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/jaktinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06883526
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07885228-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270610
DTEND;VALUE=DATE:20270611
SUMMARY:Zepuping (jaktinib): Phase 1/2 readout est. (NCT07885228)
DESCRIPTION:Zepuping (jaktinib)\, phase 1/2.\nStudy: Jaktinib for Steroid-R
 efractory Acute Graft-Versus-Host Disease\nEstimated primary completion: 1
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jaktinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 85228
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07080216-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Zepuping (jaktinib): Phase 1/2 readout est. (NCT07080216)
DESCRIPTION:Zepuping (jaktinib)\, phase 1/2.\nStudy: Study of ZG005 in Comb
 ination With Gecacitinib in Participants With Advanced Cervical Cancer\nEs
 timated primary completion: August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/jaktinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07080216
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07142837-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Zepuping (jaktinib): Phase 1/2 readout est. (NCT07142837)
DESCRIPTION:Zepuping (jaktinib)\, phase 1/2.\nStudy: Study of ZG005 in Comb
 ination With Gecacitinib and Chemotherapy for Participants With Advanced S
 olid Tumors\nEstimated primary completion: October 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/jaktinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07142837
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185633-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Zepuping (jaktinib): Phase 2 readout est. (NCT07185633)
DESCRIPTION:Zepuping (jaktinib)\, phase 2.\nStudy: Study of Gecacitinib-cor
 ticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host 
 Disease\nEstimated primary completion: 1 October 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/jaktinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07185633
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07476872-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Zepuping (jaktinib): Phase 1/2 readout est. (NCT07476872)
DESCRIPTION:Zepuping (jaktinib)\, phase 1/2.\nStudy: Gecacitinib in the Tre
 atment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (c
 GVHD).\nEstimated primary completion: 1 November 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/jaktinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07476872
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285889-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zepuping (jaktinib): Phase 1/2 readout est. (NCT07285889)
DESCRIPTION:Zepuping (jaktinib)\, phase 1/2.\nStudy: First-Line Jaktinib fo
 r Acute Graft-Versus-Host Disease (aGVHD)\nEstimated primary completion: 3
 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jakt
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07285889
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07454226-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Zepuping (jaktinib): Phase na readout est. (NCT07454226)
DESCRIPTION:Zepuping (jaktinib)\, phase na.\nStudy: ABL/JAK Inhibitors With
  Chemotherapy and Venetoclax for Ph-like ALL\nEstimated primary completion
 : 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jakti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07454226
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07883382-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20281028
DTEND;VALUE=DATE:20281029
SUMMARY:Zepuping (jaktinib): Phase 1/2 readout est. (NCT07883382)
DESCRIPTION:Zepuping (jaktinib)\, phase 1/2\, Myelofibrosis.\nStudy: An Exp
 loratory Study on the Use of Gecacitinib in Patients With Myeloid Malignan
 cies and Myelofibrosis During the Peri-transplant Period Following Allogen
 eic Hematopoietic Stem Cell Transplantation\nEstimated primary completion:
  28 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jak
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07883382
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904871-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Zepuping (jaktinib): Phase na readout est. (NCT07904871)
DESCRIPTION:Zepuping (jaktinib)\, phase na\, Myelofibrosis.\nStudy: Peri-Tr
 ansplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic 
 Hematopoietic Stem Cell Transplantation\nEstimated primary completion: 1 N
 ovember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jaktini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 904871
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938580-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Zepuping (jaktinib): Phase 2 readout est. (NCT07938580)
DESCRIPTION:Zepuping (jaktinib)\, phase 2\, Myelofibrosis.\nStudy: Gecaciti
 nib Plus Luspatercept in Patients With Myelofibrosis and Anemia\nEstimated
  primary completion: December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/jaktinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07938580
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471503-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Zepuping (jaktinib): Phase 2 readout est. (NCT07471503)
DESCRIPTION:Zepuping (jaktinib)\, phase 2\, Myelofibrosis.\nStudy: Gecaciti
 nib Pre-\, During- and Post-HSCT for Patients With Primary or Secondary My
 elofibrosis\nEstimated primary completion: 1 April 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/jaktinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07471503
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07440654-1402@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Zepuping (jaktinib): Phase na readout est. (NCT07440654)
DESCRIPTION:Zepuping (jaktinib)\, phase na\, Myelofibrosis.\nStudy: Efficac
 y and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versu
 s-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in
  Patients With Myelofibrosis\nEstimated primary completion: 1 September 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/jaktinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07440654
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
